CN108883153A - 多价和多特异性ox40结合融合蛋白 - Google Patents

多价和多特异性ox40结合融合蛋白 Download PDF

Info

Publication number
CN108883153A
CN108883153A CN201780005939.9A CN201780005939A CN108883153A CN 108883153 A CN108883153 A CN 108883153A CN 201780005939 A CN201780005939 A CN 201780005939A CN 108883153 A CN108883153 A CN 108883153A
Authority
CN
China
Prior art keywords
polypeptide
seq
amino acid
tbd
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780005939.9A
Other languages
English (en)
Chinese (zh)
Inventor
B·P·埃克尔曼
J·C·蒂默
C·哈特
K·S·琼斯
A·侯赛因
A·S·雷札伊
B·贝克兰德
R·潘迪特
M·卡普兰
L·罗森
Q·狄弗洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yinxibi Bioscience Co ltd
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of CN108883153A publication Critical patent/CN108883153A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780005939.9A 2016-01-11 2017-01-11 多价和多特异性ox40结合融合蛋白 Pending CN108883153A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662277027P 2016-01-11 2016-01-11
US62/277,027 2016-01-11
PCT/US2017/013070 WO2017123673A2 (en) 2016-01-11 2017-01-11 Multivalent and multispecific ox40-binding fusion proteins

Publications (1)

Publication Number Publication Date
CN108883153A true CN108883153A (zh) 2018-11-23

Family

ID=59275443

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780005939.9A Pending CN108883153A (zh) 2016-01-11 2017-01-11 多价和多特异性ox40结合融合蛋白

Country Status (13)

Country Link
US (3) US20170198051A1 (https=)
EP (1) EP3402507A4 (https=)
JP (3) JP7328761B2 (https=)
KR (1) KR20180098671A (https=)
CN (1) CN108883153A (https=)
AU (2) AU2017207318B2 (https=)
BR (1) BR112018013911A2 (https=)
CA (1) CA3009075A1 (https=)
IL (2) IL298686A (https=)
MX (2) MX2018008310A (https=)
RU (1) RU2022106508A (https=)
SG (1) SG11201805422WA (https=)
WO (1) WO2017123673A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113330036A (zh) * 2019-01-25 2021-08-31 信达生物制药(苏州)有限公司 结合pd-l1和ox40的双特异性抗体
CN113490686A (zh) * 2019-01-07 2021-10-08 拜科托莱夫有限公司 病原体结合蛋白
WO2022002009A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 靶向ox40的抗体及其制备方法和应用
WO2023109901A1 (en) * 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies and methods of use
CN118515763A (zh) * 2024-07-23 2024-08-20 北京百普赛斯生物科技股份有限公司 Il-6的抗体、检测试剂盒及其应用
TWI907375B (zh) * 2019-12-20 2025-12-11 加拿大商木曾路生物科技公司 多肽、蛋白質複合物及其製造方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220084444A (ko) * 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
KR20180098671A (ko) 2016-01-11 2018-09-04 인히브릭스, 인크. 다가 및 다중특이적 ox40-결합 융합 단백질
JP2019530640A (ja) * 2016-07-20 2019-10-24 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体ｏｘ４０結合分子及びその使用
WO2018027204A1 (en) * 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
ES2981272T3 (es) 2016-09-23 2024-10-08 Merus Nv Moléculas de unión que modulan una actividad biológica expresada por una célula
US20200347143A1 (en) 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20240017409A (ko) 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
AU2018394939B2 (en) 2017-12-29 2022-02-24 Ap Biosciences, Inc. Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
EP3827019A1 (en) 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
WO2020036867A1 (en) * 2018-08-13 2020-02-20 Inhibrx, Inc. Ox40-binding polypeptides and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
JP2022504802A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
CN120623346A (zh) 2018-10-11 2025-09-12 因荷布瑞克斯生物科学公司 Pd-1单结构域抗体及其治疗组合物
CN113166261A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
JP7575100B2 (ja) * 2018-11-13 2024-10-29 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫細胞活性化のための二重特異性抗体
WO2020102647A1 (en) * 2018-11-15 2020-05-22 Invenra Inc. Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins
JP2022553176A (ja) * 2019-10-17 2022-12-22 江蘇康寧杰瑞生物制薬有限公司 Ｏｘ４０／ｐｄ－ｌ１二重特異性抗体
WO2021084104A1 (en) * 2019-10-30 2021-05-06 Bioinvent International Ab Tetravalent antibody molecules
EP3940931A1 (de) 2020-07-14 2022-01-19 Siemens Aktiengesellschaft Verfahren zur herstellung eines rotors einer asynchronmaschine
WO2022023484A1 (en) * 2020-07-29 2022-02-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic and diagnostic vhh antibodies against sars-cov-2 and methods for their enhancement
WO2022243341A1 (en) * 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
WO2023089079A1 (en) * 2021-11-19 2023-05-25 Pieris Pharmaceuticals Gmbh Novel fusion protein specific for ox40 and pd-l1
CN119768433A (zh) * 2022-06-28 2025-04-04 珠海烁星生物医药科技有限公司 单特异性和多特异性抗体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157108A1 (en) * 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20130018175A1 (en) * 2009-12-14 2013-01-17 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
US20150190506A1 (en) * 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US20150355184A1 (en) * 2012-12-21 2015-12-10 Robert H. Pierce Antibodies that bind to human programmed death ligand 1 (pd-l1)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
WO2004041863A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
DK1877090T3 (da) * 2005-05-06 2014-04-14 Providence Health System Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
NZ612578A (en) * 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US8216996B2 (en) 2006-03-03 2012-07-10 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
US20130332133A1 (en) * 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
NZ594315A (en) 2009-02-17 2013-05-31 Ucb Pharma Sa Antibody molecules having specificity for human ox40
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2013008171A1 (en) * 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
PH12021553014A1 (en) * 2012-02-27 2022-09-05 Ablynx Nv Cx3cr1-binding polypeptides
US10011660B2 (en) 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
JP2015524821A (ja) * 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
JP2016514676A (ja) * 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
SG10201807625PA (en) * 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
KR20180098671A (ko) * 2016-01-11 2018-09-04 인히브릭스, 인크. 다가 및 다중특이적 ox40-결합 융합 단백질
US20200347143A1 (en) * 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157108A1 (en) * 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20130018175A1 (en) * 2009-12-14 2013-01-17 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
US20150355184A1 (en) * 2012-12-21 2015-12-10 Robert H. Pierce Antibodies that bind to human programmed death ligand 1 (pd-l1)
US20150190506A1 (en) * 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490686A (zh) * 2019-01-07 2021-10-08 拜科托莱夫有限公司 病原体结合蛋白
CN113330036A (zh) * 2019-01-25 2021-08-31 信达生物制药(苏州)有限公司 结合pd-l1和ox40的双特异性抗体
TWI907375B (zh) * 2019-12-20 2025-12-11 加拿大商木曾路生物科技公司 多肽、蛋白質複合物及其製造方法
WO2022002009A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 靶向ox40的抗体及其制备方法和应用
CN115461371A (zh) * 2020-06-30 2022-12-09 和铂医药(上海)有限责任公司 靶向ox40的抗体及其制备方法和应用
WO2023109901A1 (en) * 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies and methods of use
CN118515763A (zh) * 2024-07-23 2024-08-20 北京百普赛斯生物科技股份有限公司 Il-6的抗体、检测试剂盒及其应用
CN118515763B (zh) * 2024-07-23 2024-11-01 北京百普赛斯生物科技股份有限公司 Il-6的抗体、检测试剂盒及其应用

Also Published As

Publication number Publication date
JP2022185021A (ja) 2022-12-13
KR20180098671A (ko) 2018-09-04
MX2018008310A (es) 2019-01-28
US20170198051A1 (en) 2017-07-13
EP3402507A2 (en) 2018-11-21
US20220106397A1 (en) 2022-04-07
US20190263916A1 (en) 2019-08-29
IL260531B1 (en) 2023-01-01
WO2017123673A3 (en) 2017-08-24
MX2024004017A (es) 2024-05-08
CA3009075A1 (en) 2017-07-20
IL260531B2 (en) 2023-05-01
AU2017207318A1 (en) 2018-07-12
NZ743731A (en) 2025-06-27
AU2024200551A1 (en) 2024-02-22
AU2017207318B2 (en) 2023-12-07
JP7328761B2 (ja) 2023-08-17
US11117972B2 (en) 2021-09-14
JP2025081649A (ja) 2025-05-27
US12227584B2 (en) 2025-02-18
WO2017123673A2 (en) 2017-07-20
RU2022106508A (ru) 2022-04-05
EP3402507A4 (en) 2019-08-07
RU2018128629A3 (https=) 2020-06-16
RU2018128629A (ru) 2020-02-13
IL260531A (https=) 2018-08-30
JP2019504062A (ja) 2019-02-14
SG11201805422WA (en) 2018-07-30
IL298686A (en) 2023-01-01
BR112018013911A2 (pt) 2018-12-18

Similar Documents

Publication Publication Date Title
JP7510447B2 (ja) Ｐｄ－ｌ１－結合融合タンパク質
US11117972B2 (en) Multivalent and multispecific OX40-binding fusion proteins
TW202227494A (zh) 多特異性免疫靶向分子及其用途
JP6966330B2 (ja) Ｉｉｉ型分泌装置標的化分子
US20250122299A1 (en) ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES
RU2773052C2 (ru) Поливалентные и полиспецифические ох40-связывающие слитые белки
US20240360233A1 (en) Anti-tslpr (crlf2) antibodies
RU2789648C2 (ru) Мультивалентные и мультиспецифические 41bb-связывающие слитые белки
TW202544031A (zh) 抗tigit/抗pd-l1雙特異性抗體及其用途
TW202140556A (zh) 抗ＮＫｐ３０抗體及使用方法
HK1250991B (en) Type iii secretion system targeting molecules

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: B.P. Eckerman

Inventor after: L B Lacson

Inventor after: Q. Di frost

Inventor after: J.C. Timor

Inventor after: C. Hart

Inventor after: K.S. Jones

Inventor after: A. Hussein

Inventor after: A S Lei Rei

Inventor after: B Baekeland de

Inventor after: R. Pandit

Inventor after: M. Kaplan

Inventor before: B.P. Eckerman

Inventor before: Rosen Lee

Inventor before: Q. Di frost

Inventor before: J.C. Timor

Inventor before: C. Hart

Inventor before: K.S. Jones

Inventor before: A. Hussein

Inventor before: A S Lei Rei

Inventor before: B Baekeland de

Inventor before: R. Pandit

Inventor before: M. Kaplan

CB03 Change of inventor or designer information
TA01 Transfer of patent application right

Effective date of registration: 20240924

Address after: California, USA

Applicant after: Yinxibi Bioscience Co.,Ltd.

Country or region after: U.S.A.

Address before: California, USA

Applicant before: INHIBRX L.P.

Country or region before: U.S.A.

TA01 Transfer of patent application right